Benzinga··PrnewswireLakeShore Biopharma Gets Revised Takeover Bid at Half Premium Amid Legal Setback
LakeShore Biopharma's special committee received a revised acquisition proposal at $0.06 per share, a 50% premium, after arbitral awards of RMB576.5 million against Chinese subsidiaries.
LSBCFacquisitionbiopharmaceutical